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Glycine transporter inhibitors 
Current treatment of  schizophrenia offers 
a wide variety of  psychopharmaceuticals that 
are licensed as first-line treatments for this 
disorder. However, if  we consider their dom-
inant mechanism of  action, choice eventually 
narrows, in some instances considerably. In 
light of  the facts that one third of  patients do 
not respond to standard treatment and that 
current treatment options do not affect all 
schizophrenia symptom dimensions, it is not 
hard to conclude that there is an unsatisfied 
need which should drive the development of  
new treatment modalities focusing on other 
neurotransmitter systems beside dopamine 
and serotonin [1].
There have been recent discoveries in 
terms of  convergent and convincing evi-
dence from pharmacological, autoimmune, 
and genetic studies which have confirmed 
that impaired glutamatergic N-methyl-D-as-
partate (NMDA) receptor function can pro-
duce psychotic symptoms and that it is in-
volved in the pathogenesis of  schizophrenia. 
Glycine transporters 1 (GlyT1) play a key role 
in terminating the activity of  glycine, which is 
released into synapses from glial cells to bind 
and act at a binding site of  the NMDA recep-
tor. Glycine, with glutamate, is indispensable 
for activation of  NMDA receptors. Conse-
quently, blocking the glycine transporter in-
creases the synaptic availability of  glycine and 
thus improves NMDA neurotransmission. 
Furthermore, this enhances GABA neu-
rotransmission in the cortex, which in turn 
leads to a reduction in glutamatergic neuro-
transmission. Reduced glutamate release in 
the ventral tegmental area does not lead to 
excessive stimulation of  the mesolimbic do-
pamine pathway. The terminal goal of  GlyT1 
inhibition is the abrogation of  impaired 
NMDA receptor functionality. Exactly in this 
way GlyT1 inhibition could potentially con-
tribute to the reduction of  cognitive and neg-
ative symptoms of  schizophrenia with the 
reduction of  positive symptoms. GlyT1 in-
hibitors are also called selective glycine reup-
take inhibitors or SGRI, in analogy to drugs 
that inhibit the reuptake of  other neurotrans-
mitters, such as serotonin reuptake inhibitors 
which acts upon the serotonin transporter 
(SSRI) [1,2].
Several GlyT1 inhibitors are currently in 
the clinical testing phase, including bitopertin, 
whose chemical structure is shown in Figure 
1. We would highlight a clinical trial program 
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called “SearchLyte,” as one of  the significant 
studies related to bitopertin, which consisted 
of  six Phase III studies. Three studies target-
ed the ability to treat patients with persistent 
negative symptoms. The other three studies 
were designed to determine the ability of  the 
drug to reduce the positive symptoms of  pa-
tients who did not respond to the currently 
available antipsychotic. Two trials were dis-
continued after analysis and the remaining 
trials did not meet their primary end goals 
with the exception of  the NightLyte study. 
The aforementioned study included patients 
with a suboptimal response to treatment with 
prior antipsychotics and found that the ad-
dition of  bitopertin at a dose of  10 mg sig-
nificantly improved the PANSS scores. While 
phase III trials focused on the additional use 
of  bitopertin, a phase II / III monotherapy 
trial was also conducted. It included patients 
with acute exacerbation and compared pa-
tients treated with bitopertin to placebo and 
the active control group using olanzapine. 
A trend of  improvement in overall PANSS 
score was detected for both bitopertin (30 
mg) and olanzapine, which was the main 
endpoint of  the study. However, this was not 
significantly different from placebo for either 
drug. Such a result was considered a failed 
study, but bitopertin showed a significant 
improvement in PANSS assessment and an 
increased willingness of  treated patients for 
demission from hospital treatment compared 
to placebo. Such, in some aspects, somewhat 
disappointing results of  the bitopertin trial 
could be explained by a number of  reasons, 
for example, the first being the possibility of  
a particularly pronounced placebo response 
effect. Namely, placebo reactions are of  par-
ticular concern in studies of  negative symp-
toms that may be primary or secondary. Pri-
mary negative symptoms are inherent to the 
disease and therefore potentially respond to 
interventions targeting underlying biological 
factors, while secondary negative symptoms 
arise from factors caused by social isolation 
and stigma. The latter are likely to respond 
to psychosocial intervention and may thus 
be enhanced by regular social interactions, 
including regular assessments and medical 
examinations as part of  a clinical trial, thus 
contributing to a markedly more prominent 
placebo effect. Phase III studies were con-
ducted in chronic patients who likely devel-
oped secondary negative symptoms. Another 
problem with inclusion of  chronic patients 
in phase III studies is the fact that there is 
evidence of  glutamate abnormalities which 
are more pronounced in the early stages of  
the disease and that drugs targeting this sys-
tem can only have an effect on patients in the 
early stages of  the disease. These consider-
ations suggest that future studies should fo-
cus on patients in the early stages of  the dis-
ease [3,4].
Another prominent GlyT1 inhibitor is N-
methylglycine, which is also known as sar-
cosine. Sarcosine has been the subject of  
numerous, although predominantly small, 
schizophrenia studies that have shown its 
superiority over placebo, either alone or as 
augmentative therapy. According to some 
reports, sarcosine improved negative, cogni-
tive and depressive symptoms of  schizophre-
nia, including symptoms such as alogia and 
blunt affect [5,6]. However, further evidence 
is needed in order to confirm these facts. The 
standard dose of  sarcosine used in clinical 
studies was usually 2 grams per day, although 
there are recommendations that titration 
should be performed on a gradual basis [5,6]. 
The chemical structure of  sarcosine is shown 
in Figure 2. Sarcosine otherwise naturally oc-
curs in various foods and is sold without re-
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striction. It is extensively promoted on the in-
ternet as a supplement for “brain health” and 
for various mental health problems. Even in 
the formulation of  dietary supplements there 
is reasonable evidence that it has a true phar-
macological effect [7].
Several other GlyT1 inhibitors are also 
in the preclinical study phase, such as SSR 
504734, SSR 241586, JNJ17305600, and PF-
03463275 (2).
It is important to note that several inde-
pendent lines of  research have demonstrated 
that pharmacological inhibition of  glycine 
reuptake may also be relevant for the treat-
ment of  various other clinical conditions, 
including depression, anxiety disorders, ob-
sessive compulsive disorder, alcohol de-
pendence, epilepsy and pain. This could be 
explained by the physiological impact of  gly-
cine reuptake inhibition on either inhibitory 
glycinergic neurotransmission or NMDA 
receptor-dependent excitatory glutamatergic 
neurotransmission. However, none of  the 
proposed clinical applications can integrate 
the expected neuropharmacological effects 
of  selective inhibitors of  glycine reuptake, 
leading to the conclusion that the dual action 
of  glycine in the nervous system may explain 
why none of  these approaches have yielded 
clinically ready drugs [2, 8-12].
In conclusion, we cheer on and hope 
for further investigations of  GlyT1 inhibi-
tors, focusing on their potential to improve 
NMDA receptor functionality, as well as clin-
ically beneficial changes in symptom expres-
sion. Especially in terms of  negative and cog-
nitive symptomatology of  schizophrenia, but 
also in other potential clinical applications.
Assistant Professor Vjekoslav Peitl, MD, PhD 
Darko Vlahović, MD
Figure 1. Chemical structure of  bitopertin Figure 2. Chemical structure of  sarcosine
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